NTLA
Intellia Therapeutics, IncstockNASDAQ
intellia therapeutic's core mission is to develop curative medicines, utilizing the promise of the crispr/cas9 gene editing technology. the development of crispr/cas9 gene editing technology opens a new frontier in biomedical research and clinical intervention. adapted from a natural cellular process, crispr/cas9 permits the editing of any gene in any organism with unprecedented simplicity and flexibility. the incredible potential of this technology for treating human genetic disease inspired a group of life science veterans to create intellia therapeutics. intellia was founded in 2014 by caribou biosciences and atlas venture, along with a consortium of scientists who have helped define the space. intellia therapeutics holds exclusive access to a broad intellectual property portfolio covering the application of crispr/cas9 technology for human therapeutic use. intellia has built an experienced team of individuals to meet the challenges of bringing crispr/cas9 therapeutics to the
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 10.55 | 2026-11-12 | -13.32% | -3.548 |
| 1M | 11.58 | 2026-10-19 | -21.03% | 2.456 |
| 3M | 13.28 | 2026-08-19 | -31.14% | 2.290 |
| 6M | 11.94 | 2026-05-19 | -23.41% | 2.419 |
| 1Y | 8.24 | 2025-11-19 | +10.98% | 2.363 |
| 2Y | 14.13 | 2024-11-19 | -35.28% | — |
| 5Y | 129.48 | 2021-11-19 | -92.94% | 1.951 |
Intellia Therapeutics, Inc (NASDAQ:NTLA) stock price today is $9.15, and today's volume is 4,671,514. NTLA is down 6.397% today. The 30 day average volume is 5.29M. NTLA market cap is $1.28B with 140.36M shares outstanding.
